Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
29 Julho 2024 - 2:00AM
UK Regulatory
Roche closes acquisition of LumiraDx’s Point of Care technology to
expand access to diagnostic testing in primary care
- The acquisition of
LumiraDx’s Point of Care technology received all required antitrust
and regulatory clearances.
- LumiraDx’s transformative
Point of Care solution will complement Roche’s diagnostics
portfolio across Clinical Chemistry, Immunochemistry, Coagulation
and Molecular, and across multiple disease areas.
- By integrating LumiraDx,
Roche will further its ambition to deliver decentralised solutions
that expand global access to testing in primary care settings
worldwide.
Basel, 29 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
announced today the completion of the acquisition of LumiraDx’s
Point of Care technology, following the receipt of all required
antitrust and regulatory clearances. Roche will now embark on the
full integration of the company’s innovative multi-assay point of
care platform and the related R&D, operational and commercial
sites into its global organisation.
Through this acquisition, Roche complements its diagnostics
portfolio with a simple-to-use platform that consolidates a wide
range of immunoassay and clinical chemistry tests on a single
instrument, with the future potential to expand into molecular
testing. The innovative solution will allow Roche to further expand
its offering in decentralised patient care, and drive global access
to timely and actionable diagnostic results.
“Access to diagnostic testing is critical for the delivery of
healthcare worldwide and we are confident that the LumiraDx
platform and technology will help us expand the availability of
testing, especially in settings such as primary care and low and
middle income countries,” said Matt Sause, CEO of Roche
Diagnostics.
Veronique Ameye, Chief Executive Officer of LumiraDx, added: “We
are absolutely delighted to continue our journey as part of Roche
Diagnostics. Being an integral part of the Roche network opens the
door to realising the full potential of our Point of Care
technology, and to increasing patient access to community-based
healthcare around the world. We look forward to writing the next
chapter in our shared efforts to deliver even greater impact for
patients.”
Roche announced the signing of its agreement to acquire
LumiraDx’s Point of Care technology at the end of 2023.
Continued Partnership with the Bill & Melinda Gates
Foundation
As part of the acquisition, Roche will continue to partner with the
Bill & Melinda Gates Foundation on the further expansion of the
platform’s molecular diagnostic capabilities through the
development of an innovative and rapid point of care molecular
tuberculosis test. Today, we are still facing an estimated gap of
more than 4 million people worldwide whose tuberculosis remains
undiagnosed - and as a consequence, untreated.1 With a
lower-cost solution that is ideally suited to providing diagnostics
at the point of care in remote settings, this test aims to enable
better tuberculosis detection and treatment to achieve global
epidemic control targets.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first
industrial manufacturers of branded medicines, Roche has grown into
the world’s largest biotechnology company and the global leader in
in-vitro diagnostics. The company pursues scientific excellence to
discover and develop medicines and diagnostics for improving and
saving the lives of people around the world. We are a pioneer in
personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide
the best care for each person we partner with many stakeholders and
combine our strengths in Diagnostics and Pharma with data insights
from the clinical practice.
In recognising our endeavour to pursue a long-term perspective
in all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the fifteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the
Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
References
[1] World Health Organization (WHO)
Global Tuberculosis Report 2022. Accessed 30 May 2024.
https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD
Phone: +41 79 407 72 58 |
Sileia
Urech
Phone: +41 79 935 81 48 |
Nathalie
Altermatt
Phone: +41 79 771 05 25 |
Lorena
Corfas
Phone: +34 620 29 25 51 |
Simon
Goldsborough
Phone: +44 797 32 72 915 |
Karsten
Kleine
Phone: +41 79 461 86 83 |
Nina
Mählitz
Phone: +41 79 327 54 74 |
Kirti
Pandey
Phone: +49 172 6367262 |
Yvette
Petillon
Phone: +41 79 961 92 50 |
Dr
Rebekka Schnell
Phone: +41 79 205 27 03
|
Roche Investor Relations
Dr Bruno
Eschli
Phone: +41 61 68-75284
E-mail: bruno.eschli@roche.com |
Dr Sabine
Borngräber
Phone: +41 61 68-88027
E-mail: sabine.borngraeber@roche.com |
Dr Birgit
Masjost
Phone: +41 61 68-84814
E-mail: birgit.masjost@roche.com |
|
Investor Relations North America
Loren
Kalm
Phone: +1 650 225 3217
E-mail: kalm.loren@gene.com |
|
- 29072024_MR_Roche_LumiraDX_closing_en
Roche (LSE:0QQ6)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Roche (LSE:0QQ6)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024